Novo Nordisk AS (NYSE:NVO)
$ 49.07 -0.21 (-0.43%) Market Cap: 217.13 Bil Enterprise Value: 236.14 Bil PE Ratio: 11.51 PB Ratio: 7.06 GF Score: 71/100

Q3 2024 Novo Nordisk A/S Earnings Presentation (London-Based Investors) Transcript

Nov 07, 2024 / 01:15PM GMT
Release Date Price: $107.63 (+2.15%)

Nov 07, 2024 / 01:15PM GMT
Presentation (London-Based Investors)
Nov 07, 2024 / 01:15PM GMT

=====================
Corporate Participants
=====================
* Karsten Munk Knudsen
Novo Nordisk A/S - Chief Financial Officer, Executive Vice President
* Camilla Sylvest
Novo Nordisk A/S - Executive Vice President - Commercial Strategy and Corporate Affairs
* Martin Lange
Novo Nordisk A/S - Executive Vice President - Development
* Jacob Martin Rode
Novo Nordisk A/S - Investor Relations

=====================
Conference Call Participants
=====================
* Sachin Jain
Bank of America - Analyst
* Emily Field
Barclays - Analyst
* Richard Vosser
JPMorgan - Analyst
* Richard Parkes
BNP Paribas Exane - Analyst
* James Quigley
Goldman Sachs - Analyst
* Rajesh Kumar
HSBC - Analyst
* Simon Baker
Redburn Atlantic - Analyst
* Kerry Holford
Berenberg - Analyst
* Emmanuel Papadakis
Deutsche Bank - Analyst

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot